TNXP
HEALTHCARETonix Pharmaceuticals Holding Corp
AI Insight
What's Moving TNXP Today?
No stock-specific AI insight has been generated for TNXP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.03$69.97
$12.10
Fundamentals
Market Cap$191M
P/E Ratio—
EPS$-14.66
Dividend Yield—
Dividend / Share—
ROE-72.3%
Profit Margin—
Debt / Equity—
Trading
Volume391K
Avg Volume (10D)—
Shares Outstanding15.9M
TNXP News
21 articles- Director Carolyn Taylor buys Tonix Pharmaceuticals (TNXP) shares in open marketStock Titan·Jun 15, 2026
- We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn RateYahoo Finance·Jun 13, 2026
- Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026Yahoo Finance·Jun 11, 2026
- Why Is TNXP Stock Rising Today?Stocktwits·Jun 8, 2026
- Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesYahoo Finance·Jun 8, 2026
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingYahoo Finance·May 28, 2026
- Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical ImmunologyYahoo Finance·May 27, 2026
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual MeetingYahoo Finance·May 26, 2026
- TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. PatientsYahoo Finance·May 20, 2026
- Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026Yahoo Finance·May 14, 2026
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in MayYahoo Finance·May 12, 2026
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational HighlightsYahoo Finance·May 11, 2026
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. PatientsYahoo Finance·May 6, 2026
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins UniversityYahoo Finance·Apr 29, 2026
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026Yahoo Finance·Apr 23, 2026
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug DevelopmentGlobeNewswire Inc.·Apr 15, 2026
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026Yahoo Finance·Mar 31, 2026
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial PainYahoo Finance·Mar 26, 2026
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026Yahoo Finance·Mar 23, 2026
- TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial LaunchYahoo Finance·Mar 23, 2026
- Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026Yahoo Finance·Mar 18, 2026
All 21 articles loaded
Price Data
Open$11.96
Previous Close$11.96
Day High$12.30
Day Low$11.84
52 Week High$69.97
52 Week Low$10.03
52-Week Range
$10.03$69.97
$12.10
Fundamentals
Market Cap$191M
P/E Ratio—
EPS$-14.66
Dividend Yield—
Dividend / Share—
ROE-72.3%
Profit Margin—
Debt / Equity—
Trading
Volume391K
Avg Volume (10D)—
Shares Outstanding15.9M
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—